Hoffmann-la Roche Inc.

F. Hoffmann-la Roche Ag

Omar Jose Morales

Norman Kong

Shaoqing Chen

John Anthony Moliterni

Nicholas J S Huby

Yan Lou

Yimin Qian

Sung-Sau So

Francisco Javier Lopez-Tapia

Timothy D Owens

Roland Joseph Billedeau

Rama K Kondru

Kshitij Chhabilbhai Thakkar

Jutta Wanner

Nicholas John Silvester Huby

This application discloses compounds according to generic Formula I: wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.

Inhibitors of bruton's tyrosine kinase

The present invention relates to compounds of the formula methods for the preparation thereof, and methods for their use. The compounds are useful in treating diseases characterized by the hyperactivity of MEK. Accordingly the compounds are useful in the treatment of diseases, such as cancer, cognitive and CNS disorders, and inflammatory/autoimmune diseases.

Substituted hydantoins

This invention relates to compounds of formula I: or pharmaceutically acceptable salts thereof,wherein R1, R2, R3, R4, R5, and R6 are described in this application. These compounds inhibit the enzymes MEK 1 and MEK2, protein kinases that are components of the MAP kinase signal transduction pathway and as such the compounds will have anti-hyperproliferative cellular activity.

Growing community of inventors

New Milford, NJ, United States of America

Omar Jose Morales